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Introduction
Prothymosin alpha (PTα) was originally isolated
from thymus and initially considered as a thymic hor-
mone. It is a peptide composed in humans from 111
amino acids and it shows a wide distribution in differ-
ent tissues and organs [1]. Its physiological role
remains obscure. However, because of its dominant
intra-nuclear localization a role of PTα in the control
of cell proliferation and/or of apoptosis was suggested
[2,3]. In some recent studies an overexpression of PTα
was found in malignant tumors, like gastric [4],
prostate [5,6] and thyroid cancers [7,8]. The quoted
authors suggest that PTα may be useful as a marker of
malignancy. Although pituitary adenomas are consid-
ered as benign tumors, they markedly differ from case
to case in their aggressiveness, related to the ability to
invade the adjacent structures and to the growth poten-
tial. To our knowledge, there are no data on PTα
expression in pituitary adenomas except the prelimi-
nary study published by one of us several years ago
[9,10]. Recently, a group from Greece developed and
characterized an antibody against the C-terminal frag-
ment 101-109 of human PTα, suitable for immunohis-
tochemistry [6]. The present study reports on the
immunohistochemical detection of PTα in different
subtypes of pituitary adenomas using this antibody.
Material and methods
The study was performed using the archival material of 40 pitu-
itary adenomas stored as paraffin blocks. This material included 6
cases of acromegaly, 3 cases of prolactinoma, 24 cases of clinical-
ly non-functioning pituitary adenomas (CNFPA, including 8 ade-
nomas expressing solely gonadotrophins or free α-subunit), 7
cases of Cushing's disease (including one case of Nelson's syn-
drome). The paraffin sections of the tumors were immunostained
with antibody against the C-terminal fragment (101-109) of pro-
thymosin alpha (kindly received from Dr Evangelia Livaniou,
Institute of Radioisotopes and Radiodiagnostic products, National
Science for Scientific Research "Demokritos", Athens, Greece) or
with anti-Ki-67 antigen (MIB-1) antibody (Dako-Cytomation,
Denmark). The primary antibodies were applied in the working
solution 1:100. The control slides were stained with the omission
of the primary antibody. The hormonal phenotype of the investi-
gated pituitary adenomas has been established previously by
means of immunostaining with antibodies to pituitary hormones
(GH, PRL, FSH, LH, TSH, ACTH and α-subunit). The visualiza-
tion of reactions was done by means of streptavidin-biotin-peroxi-
dase technique with use of StreptABC/HRP kit (Dako-Cytoma-
tion) and 3,3'-diaminobenzidine as chromogen. The number of
PTα-immunopositive and Ki-67-immunopositive cell nuclei was
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Fig. 1. Immunostaining with anti-PTα antibody in the clin-
ically non-functioning, ACTH-immunopositive recurrent
pituitary adenoma (second recurrence) of the male patient
– ZL. Arrows indicate PTα-immunopositive (brown) cell
nuclei. The PTα-immunopositive microvessels (dark
brown) can also be seen (original magnification ×400).
Fig. 2. Immunostaining with anti-PTα antibody in the clin-
ically non-functioning, ACTH-immunopositive pituitary
adenoma of the male patient WW. The cell nuclei are
mostly immunonegative (original magnification ×400).
Fig. 3. The same tumor as on Fig. 2. The negative control
(without the primary antibody) (original magnification
×400).
The numeric data were analyzed statistically using ANOVA
followed by LSD test; statistical significance was at level p<0.05.
Results
The strong immunostaining with PTα antibody was
found in a subpopulation of tumor cell nuclei and in
the endothelium of intratumoral blood vessels. Less
intensive immunostaining was also noticed in adeno-
ma cells cytoplasm (Fig. 1, 2). No staining was found
in control slides, where the primary antibody was
omitted (Fig. 3). The percentage of PTα-immunoposi-
tive nuclei was clearly higher in recurrent adenomas
than in primary tumors (19.7±3.9% vs 3.5±0.8%;
mean±SEM, p<0.001). However, there was no correla-
tion between the frequency of PTα-immunopositive
nuclei and Ki-67 index (data not shown). Moreover,
there was no significant difference in Ki-67 index
between recurrent and primary adenomas (2.59±0.96
vs 4.03±1.4, mean±SEM). The mean frequency of
PTα-immunopositive cell nuclei in dependence on the
hormonal phenotype of adenomas is shown in Fig. 4.
As it can be seen there, the highest percentage of PTα-
immunopositive subpopulation of cell nuclei occurred
in gonadotropinomas. No differences were observed in
cytoplasmic PTα immunostaing either between recur-
rent and non-recurrent tumors or in dependence of hor-
monal phenotype of the tumor, except the corti-
cotropinomas in Cushing's disease, which demonstrate
a slightly higher cytoplasmic expression.
Discussion
The preferential nuclear PTα immunostaining in pitu-
itary adenomas is concordant with our earlier data [9]
and compatible with the observations concerning the
other tissues either normal or neoplastic [cited in the
introduction]. The most important finding of the pres-
ent study is showing that the nuclear expression of
PTα is significantly higher in recurrent adenomas in
comparison to primary tumors. This observation cor-
roborates with our earlier preliminary study [9,10].
Nuclear expression of PTα does not reveal the signifi-
cant differences depending on different hormonal phe-
notypes of adenomas, except the significantly higher
number of PTα-immunopositive nuclei in
gonadotropinomas. However, this result probably
depends on the highest rate of recurrent tumors within
this group. The risk of recurrence of the pituitary ade-
noma after surgery is complex and it depends on the
time of diagnosis and skillfulness of the neurosurgeon,
but also on the tumor aggressiveness. The latter
includes the tumor invasiveness, which enables the
total excision of the tumor, and the high proliferation
potency. It was shown that recurrent pituitary adeno-
mas exhibit higher levels of different proliferation
markers, like silver staining nuclear organizer regions
– AgNOR, proliferating cells nuclear antigen – PCNA
or Ki-67 than non-recurrent pituitary tumors [11-15].
However, according to other authors, Ki-67 index is
not a predictor of tumor recurrence [16]. Turner and
Wass [17] conclude that although there is a relation-
ship in many pituitary tumors between Ki-67 index
and their invasiveness and recurrence, the low Ki-67
index can be noticed in aggressive tumors and, in con-
trast, the high proliferation index may occur in the
indolent adenomas. In the present study, we did not
find a significant difference in Ki-67 index between
recurrent and primary tumors. These data taken togeth-
er suggest that the value of Ki-67 labeling alone is lim-
ited as prognostic factor. Possibly, PTα immunostain-
ing may be helpful also in predicting the pituitary
tumor recurrence. However, this conclusion needs to
be confirmed in further prospective studies. Another
sites of the strong PTα immunostaining are intra-
tumoral microvessel walls. In the larger vessels it can
be observed that the PTα immunostaining concerns
mostly endothelium. It remains unclear whether
endothelial cells are able to express intrinsically the
large amounts of PTα or the peptide produced in
tumoral cells preferentially bind to endothelium. Inde-
pendently of these explanations, the strong immunos-
taining of PTα within the endothelium corroborates
with the suggested pro-angiogenic role of this peptide
[18]. Moreover, PTα may be useful as an immunohisto-
chemical marker of the intra-tumoral microvasculature. 
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Fig. 4. Percentages of PTα-immunopositive cell nuclei in depend-
ence of the hormonal phenotype of pituitary adenomas. (CNFPA –
clinically non-functioning pituitary adenomas).
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